Abstract: Ultrasound is the most useful imaging technique for guiding biopsies and fine-needle aspirations that are performed percutaneously. It is a safe and accurate method to guide needles using real-time imaging into abdominal and pelvic organs and masses. Its advantages over computed tomographyYguided biopsies are that it can be done portably, is less expensive, and does not use ionizing radiation. Even lesions as small as 1 cm can be biopsied assuming the procedure can be performed safely and the mass can be visualized sonographically.
U ltrasound is the most useful imaging technique for guiding percutaneous and endoscopic biopsies. It is safe and accurate and allows one to guide a needle in a real-time manner into organs, masses, and lymph nodes. 1, 2 NolsLe et al, 2 in a review of almost 8000 ultrasound-guided percutaneous procedures, found a complication rate of only 0.187% and a mortality rate of 0.038%. Even small masses down to 1.0 cm can be successfully biopsied depending on their location and sonographic visibility. 1, 3 Its major advantage over computed tomography (CT) is that it is portable, allows real-time visualization of the biopsy needle and its tip, is less expensive, and most importantly does not use ionizing radiation. 4 Its greatest disadvantage is that that it is more operator dependent. Also, some lesions or organs are difficult to see and may not be amenable to biopsy because of the patient's body habitus or intervening structures such as air or bone. In those cases, CT guidance might be preferable.
The component parts in performing a biopsy are as follows:
1. Review the clinical indications for performing the biopsy to make sure it is indicated. Look at prior imaging studies if available to ascertain if the biopsy can be performed safely using ultrasound guidance. 2. Ensure the coagulation status of the patient is within a range that allows the biopsy to be performed safely. If not, consult with the patient's physician, including a hematologist if necessary, to see if the abnormal values can be corrected. 3 . Properly obtain informed consent. 4 . Perform the biopsy following the appropriate administration of local anesthesia. 5. Perform care of the patient after biopsy. 6 . Review quality assurance of pathology reports to determine the percentage of failed biopsies.
Coagulation Status of the Patient
In this section of the article, we describe our approach to screening patients by obtaining coagulation status before all of our procedures. We acknowledge that this is a complex and controversial issue with the literature providing rather confusing guidelines. This is why different medical institutions may have their own standards for performing screening coagulation tests on their patients based on their experience with complications.
When a procedure is scheduled in our ultrasound department, we first review the clinical indications and imaging studies to ensure that the procedure is both clinically indicated and safe to perform. We then have to assess the coagulation status of the patient to minimize the most feared complication related to the procedure, namely, postbiopsy hemorrhage. Because a large number of our biopsies are scheduled on an outpatient basis, we as radiologists have very little clinical information on these patients other than the history relevant to the procedure itself. For patients who are scheduled for a solid organ biopsy (liver, kidney, spleen, adrenal, and pancreas), we routinely screen them by requesting a complete blood count, a prothrombin time (PT) and international normalized ratio (INR), and activated partial thromboplastin (aPTT). We do not require repeat coagulation tests if results are available from the past 3 months unless the patient's clinical status demands it (history of lupus, chronic use of anticoagulation therapy, patients with known bleeding disorders). As mentioned at the beginning of this section, we recognize that ordering coagulation tests is at the discretion of the physician performing the procedure. Malloy et al 5 recently published extensive detailed guidelines for coagulation status and management based on the risk of bleeding of a large group of vascular and nonvascular percutaneous procedures. In general, they classify intraabdominal and transabdominal biopsies as ''moderate risk'' for bleeding, whereas renal biopsies are considered to have a more ''significant risk'' of bleeding. 5 Their consensus panel concluded that only INR and aPTT (for patients on heparin) would be necessary for the moderate risk for bleeding group. They recommended adding a platelet count and hematocrit level for the significant risk group. We also obtain a list of the patients' medications, paying specific attentions to ones that may alter coagulation. This allows correct interpretation of all test results and a better assessment of comorbidities along with avoiding unnecessary rescheduling or cancellation of procedures.
Our accepted cutoff numbers for each of the coagulation parameters are summarized in Table 1 . It should be emphasized that these are general guidelines that we follow; however, they can be altered on a case-by-case basis depending on the patient's clinical condition. Based on a wide review of the literature and their experience, O'Connor et al 6 have suggested cutoff INR values of up to 3.0 for procedures performed using a 20-gauge needle and up to 2.0 for most other procedures including tissue biopsies, transhepatic cholangiograms, and placement of percutaneous catheters. They consider a safe platelet count level of 25,000/KL or greater for soft tissue biopsies and other procedures and have no specific cutoff value when doing FNAs using a 20-gauge needle. It should be remembered that a platelet count is only a number and does not give us information regarding platelet function. Some advocate the use of the bleeding time to assess platelet function; however, it has limited sensitivity and specificity in predicting the risks of hemorrhage related to invasive procedures. For this reason, we do not routinely use the bleeding time when performing our procedures. Others consider safe criteria defined as a platelet count of 50,000/KL and an INR of less than 1.6. 7 Caturelli et al 8 performed 229 liver punctures under ultrasound guidance on 85 patients using fine needles (20-and 22-gauge) for diagnostic purposes or therapeutic injection of ethanol. Their patients had platelet levels of less than 50,000/mm 3 and/or PT times that were less than 50% of controls, and none had any bleeding complications. In addition, none of their patients received any type of blood products to correct their coagulation parameters. 8 Interpretation of the PT, INR, and aPTT results is performed in conjunction with any relevant history pertaining to chronic liver disease, malabsorption syndromes, and malnutrition. A large number of our scheduled liver biopsy patients have underlying liver disease, most commonly hepatitis and cirrhosis, and any of these conditions may abnormally prolong coagulation parameters, particularly the PT. Knowledge of the patients' prescribed medication specifically the intake of aspirin, clopidogrel (Plavix; Bristol-Myers Squibb, New York, NY), warfarin, or heparin is crucial to the correct interpretation of homeostasis. Aspirin and clopidogrel are both platelet inhibitors, and we instruct patients to stop taking them 5 to 7 days before the procedure. This is another topic that is up for debate according to the literature and varies from one institution to the next. Whereas Winter et al 9 seem to be in agreement with our recommendations, Malloy et al 5 have slightly different guidelines. They advise withholding clopidogrel 5 days before procedures that are both in the moderate risk and significant risk for bleeding, whereas aspirin is stopped only 5 days before a procedure in the last groups of patients. On the other hand, Atwell et al 7 studied the overall incidence of significant hemorrhage following 15,181 percutaneous image-guided biopsies from a variety of solid organs in patients taking aspirin within 10 days of the procedure. They concluded that overall the risk of major hemorrhage was not significantly increased in patients on aspirin (0.6%) compared with those not on aspirin (0.4%).
Withholding clopidogrel is relatively easy for the group of patients who take these drugs as a preventive measure, that is, to avoid any cardiovascular events. However, patients who have coronary artery stents or a history of prior heart attack or stroke and those with peripheral artery disease reportedly have a 3 times higher risk of developing stent thrombosis, transient ischemic attacks, and ischemic strokes if they discontinue their aspirin intake. 10, 11 When it can be stopped safely, clopidogrel should be restarted as soon as possible after the procedure using a loading dose. 12 All of this should be done after consulting with the referring physician to ensure that the benefits of the procedure outweigh the risks of discontinuing clopidogrel, even temporarily.
Patients taking either warfarin or heparin are the ones most likely to have bleeding complications following a procedure. Warfarin inhibits the formation of vitamin KYdependent coagulation factors, thus prolonging the INR and PT, whereas heparin inhibits coagulation factors of the intrinsic pathway prolonging the aPTT. Low-molecular-weight heparin (LMWH) has antiYXa factor activity and, to a lesser degree, inhibition of all the coagulation factors of the intrinsic pathway; however, it does not alter the aPTT. We instruct our patients to stop warfarin 3 to 5 days before a procedure and advise bridging anticoagulation therapy with heparin or LMWH for those with the greatest risks of thromboembolic accidents. Alternatively, warfarin dosage should be decreased to adjust the INR level down to 1.5 to 2. When using heparin or LMWH bridging therapy, they should be stopped 6 and 12 hours, respectively, before the biopsy.
For nonsteroidal anti-inflammatory drugs (NSAIDs) other than aspirin, patients are instructed to take them as directed by their treating physicians. Although some NSAIDs have antiplatelet aggregation function, they are short-acting drugs, and the effect is quickly reversible compared with most other anticoagulants. Table 2 shows the guidelines on how we manage patients on anticoagulation therapy in our department before scheduling a biopsy. When the hemostatic status is compromised and the PT, aPTT, and INR cannot be corrected by adjusting anticoagulation therapy, patients should be given the option of having either platelet transfusions or fresh frozen plasma (FFP). We usually recommend using 2 to 4 units of platelets or FFP approximately 1 hour before the procedure, with preferably the last unit being transfused during the biopsy. We do not routinely recheck the INR, PT, and aPTT after these transfusions. According to the literature, however, there are no set guidelines to determine the exact dose of FFP needed to correct only mildly elevated INR values, and most of the time, the number of units used is insufficient to correct it. 13 6 When confronted with a situation where the patient would require blood product transfusions to correct their coagulopathic state, we generally discuss the different options with the referring physician, making sure that we carefully weigh the risks of the procedure against the benefits of obtaining a pathological diagnosis.
PERFORMANCE OF THE BIOPSY PROCEDURE
Before each procedure, patients are consented by the radiologist performing the biopsy. We explain every step of the process and describe the potential complications associated with each individual biopsy and the alternatives to the biopsy.
We make sure that the patient has either somebody available to drive him/her home. Patients are required to sign a consent form, which is witnessed by the sonographer or nurse available at the time. In addition to this, a ''time out'' is called by the sonographer with the radiologists in attendance before the procedure itself, at which time the patient's identity and type of biopsy are verified.
We no longer have patients fast and in fact encourage them to have a light meal before the procedure. Before starting any biopsy, we make sure the patient fully understands the procedure. Reassuring the patient and keeping them informed throughout the process are very important. This helps relieve anxiety and apprehension, and using these techniques, we have noted anecdotally a reduction in the number of vasovagal reactions that occur.
Before starting the biopsy, all the necessary supplies to perform the procedure efficiently in the least amount of time should be readily available in the room. We use a 5-to 7-mHz curved array probe for deep biopsies to which a biopsy guide can be attached. For more superficial biopsies, we use a 10-to 12-mHz linear array probe and a freehand technique. The transducer face of the probe is covered with some ultrasound gel and placed into a sterile plastic sheath. A rubber band is put around the transducer face to keep the gel in place, and a small amount of sterile gel is used to provide good acoustic contact between the sheathed transducer and the patient's skin. Some authors prefer not to use the plastic sheath as it may degrade the image. 1 They rely on cleaning the transducer with povidone-iodine (Betadine), which works well at preventing infection. 15 Over the years, we have gone away from using conscious sedation for performing biopsies and rely on the liberal use of local anesthesia (1% lidocaine). We tell patients that the biopsy procedures that we do are similar to going to the dentist. Although the administration of the lidocaine initially does hurt, once it is fully administered, patients should feel no pain. The interventional radiologists in our department use conscious sedation as their procedures are more complex and lengthy, whereas our biopsy takes only minutes to perform once the local anesthesia has been administered. Mueller et al 16 showed that patients having visceral biopsies experienced more pain with local anesthesia alone versus local anesthesia and conscious sedation. The satisfaction scores, however, were similar for each group. The administration of conscious sedation lengthens the procedure and requires constant monitoring of the patient. Patients also may act differently and may not obey simple commands such as ''hold your breath,'' which may be required for some liver and kidney biopsies.
The skin entry site should be cleansed and draped in a sterile fashion and should not be close to a scar as this can make it difficult to advance the biopsy needle. Our biopsy trays contain either povidone-iodine (Betadine) or chlorhexidine as the topical antiseptic agent. We have no specific preference for using one over the other. The surgical literature seems to be divided as to their efficacy in preventing infection, with some stating that chlorhexidine is comparable to povidone-iodine (Betadine). 17 Others conclude that the former performs better than the latter as a preoperative antiseptic. 18, 19 Advantages of chlorhexidine include that it does not cause itching and does not leave a brownish stain on the skin like Betadine. 19 In our patients who are all adults, we use up to 25 mL of 1% lidocaine (10 mg/mL) to achieve complete local anesthesia. The maximum dosage of lidocaine 1% that can be administered is 4.5 mg/kg not to exceed 300 mg. Local anesthesia is achieved for up to 30 minutes or more using this dosage. Adverse effects are very rare and involve the central nervous system (disorientation, convulsions, respiratory depression, coma), cardiovascular system (bradycardia, cardiovascular collapse), and even more rarely allergic reactions. It is important to make sure the skin is properly anesthetized by injecting 2 to 3 mL of lidocaine intradermally (not subdermally) by making a wheal. This is done using a 25-gauge, quarter-inch needle. The soft tissues down to the biopsy site are then anesthetized using ultrasound guidance and a 20-or 22-gauge spinal needle. As the needle is advanced, the plunger of the syringe should be drawn back before injecting to make sure the needle tip is not in a blood vessel. Patients usually do not experience much pain as the needle goes through fatty tissue. When the needle traverses the muscular layer, however, the patients may experience some pain. They should be forewarned of this as one sees the needle-tip approach the muscle layer on the ultrasound monitor (see Video, Supplemental Digital Content [SDC] 1, http://links.lww.com/RUQ/A48 which demonstrates deep injection of lidocaine to the level of the biopsy site). If the chosen biopsy tract traverses into the peritoneum, we make sure to administer 3 to 5 mL of lidocaine directly on the peritoneal surface before advancing the needle through it. The pain elicited by advancing through the peritoneum that is not properly anesthetized can lead to a vasovagal reaction. Once we have achieved good local anesthesia, we remove the needle and make a small 3-mm nick in the skin to allow easy movement of the needle. This nick is made bystretching the skin transversely and introducing a scalpel blade at a 45-degree angle into the skin, with the sharp edge facing upward. The skin is then cut in an upward fashion so as to avoid cutting into the deeper soft tissues. The biopsy needle is gently pushed through the nick and using ultrasound guidance is advanced through the anesthetized soft tissues down to the organ or mass on which to perform a biopsy.
If there is difficulty visualizing the needle tip, we move the focal zone of the transducer to its expected position. We also adjust the acoustic output appropriately, as seeing the needle tip, particularly in echogenic soft tissues can be especially difficult. 20 Moving the needle tip to and fro (''pump maneuver'') is also helpful as is the use of color flow Doppler.
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This technique is especially useful when using fine needles and a steep angle. 22 If the needle has a stylet, moving this back and forth in the barrel of the needle improves needle-tip visibility. 22 If the target organ moves with respiration, breathing should be suspended for 3 to 5 seconds while performing the biopsy. It is often useful to have a few practice runs doing this to make sure the patient can correctly follow the command. We usually take a video clip documenting the biopsy needle entering and exiting the tissue being biopsied (see Video, SDC 2, http://links.lww.com/RUQ/A49, which demonstrates the biopsy needle entering and exiting the liver).
In cases requiring a coaxial technique, we use the coaxial needle to administer the lidocaine to the level of biopsy site using ultrasound guidance. The tip of the needle is usually easily seen while the lidocaine is administered as it produces a swirl of echoes in the soft tissues around the tip. The lidocaine left in the needle is removed by fully inserting the blunttipped trocar before inserting the biopsy needle.
Most of the abdominal and pelvic biopsies are core biopsies, done using an automated, spring-loaded, 18-gauge cutting needle that has a variable throw (13, 23 , or 33 mm). Overall, they provide a diagnosis up to 94% of the time. 23Y25 Arabas et al 26 have shown that a 14-to 18-gauge cutting needle is better in providing a diagnosis than a 20-gauge cutting needle. In 841 patients, the larger needle provided a pathological diagnosis in 96.8% versus 84.1% for the smaller needle. The needle can be introduced directly to the target site by itself or through a 17-gauge coaxial needle, which we favor. The core specimens obtained are placed in 10% formalin solution or on a Telfa pad moistened with nonbacteriostatic saline. If a smear is needed for cytopathology, the core can be placed on a glass slide, and a second glass slide can be gently brushed over the specimen (touch prep). This will deposit some cellular materials on the glass slide, which can then be smeared and stained for cytopathologic analysis.
In cases where lymphoma is the possible diagnosis, we do FNAs. At our institution, FNAs are widely used for the diagnosis of hematologic neoplasms. Our cytopathologists perform flow cytometry to detect cell markers (immunophenotyping) on a small sample of cells. This allows accurate differential diagnosis between reactive processes and subclassification of B-cell non-Hodgkin lymphomas and T-cell nonHodgkin lymphomas. We use 22-gauge needles for the FNAs in addition to core biopsies, using a coaxial technique. The FNA needles should be long enough to extend out beyond the tip of the coaxial needle. 27 The 17-gauge coaxial needle is much easier to visualize sonographically than the 22-gauge needle and is less likely to bend out of the field of view. The tip of the fineneedle that is beyond the tip of the coaxial needle is easily seen within the mass being sampled because of its back-and-forth motion (Fig. 1 , see Video, SDC 3, http://links.lww.com/RUQ/A50, which demonstrates FNAs of the small focal liver lesion seen on the CT scan. Lymphoma was the suspected diagnosis). Before starting the sampling process, we attach an air-filled syringe to the needle, which acts as a handle for the back-and-forth motion needed to perform the FNA The air-filled syringe is then used to expel the cellular contents in the barrel of the needle without having to separately attach/disattach the needle. Our cytopathologists prefer us not to apply suction to the syringe, and so we use a nonaspiration technique that provides diagnostically superior specimens. 28, 29 This technique works better with larger-bore needles. 27 The cellular material is drawn into the barrel of the needle by capillary action. 29 The use of suction tends to draw blood into the needle, making it difficult to visualize the native cells. We do a minimum of 3 FNAs (to ensure adequacy of sampling because our cytopathologists are not always present during the procedure), which are smeared onto slides for cytopathology and then rinsed out of the needle into RPMI medium for flow cytometry. After the FNAs, we also perform at least 3 core biopsies through the coaxial needle. These additional cores are performed as a backup for immunohistochemistry or in cases where diagnoses other than lymphoma are in the differential.
LIVER BIOPSY
The usual indications for performing a liver biopsy are for diagnosing hepatocellular disease and the etiology of a hepatic mass 30 (Table 3) . A biopsy should be performed on coagulopathic patients who need a biopsy because of diffuse hepatocellular disease, using the transjugular approach. 31, 32 When this is not a problem, we do our liver biopsies using a subcostal approach in the midline epigastrium, taking our core from the left lobe of the liver (see Video, SDC 4, http://links.lww.com/RUQ/A51, showing a biopsy of the left lobe of the liver using a shortthrow technique in a patient with sarcoidosis). If the left lobe is small and not easily amenable, we place the patient in the left lateral decubitus position and use a subcostal approach. Less preferably, we would use the intercostal route. We make sure to administer 3 to 5 mL of lidocaine directly onto the liver surface using ultrasound guidance. To limit the number of passes to one, we use an automated, spring-loaded, 18-gauge cutting needle with a throw of 33 mm that provides a nice long specimen (see Video, SDC 5, http://links.lww.com/RUQ/A52, which demonstrates the technique for a core biopsy from the left lobe of the liver using a deep-throw technique). 23, 27 For biopsy of a liver mass, we usually use a coaxial technique 3, 26 (see Videos, SDC 6, http://links.lww.com/RUQ/A53, which demonstrates FNAs of a small focal liver lesion, and SDC 7, http://links.lww.com/RUQ/A54, which demonstrates subsequent core biopsy of the same liver lesion). Advantages of this technique over the noncoaxial method for focal lesions are that multiple samples can be obtained once the coaxial needle is in place and the capsule of the organ is pierced only once. There is also evidence in the literature that this method decreases the risk of tumor seeding along the needle track, and this is crucial in potential liver transplant recipients. 33 Maturen et al 33 found a 0% rate of tumor seeding in 101 patients with hepatocellular carcinoma using a 17-gauge coaxial system and an 18-gauge biopsy cutting needle. Hatfield et al 34 compared the complication rate of performing liver and renal biopsies using imaging guidance with a coaxial system (764 biopsies) and without a coaxial needle (296 biopsies). They found no differences between the 2 methods, with minor complications occurring in 3.4% and 2.6% of the cases when using the noncoaxial and the coaxial techniques, respectively. Major complications requiring blood transfusions or surgery occurred in 1.0% of noncoaxial and 0.9% of coaxial techniques.
If the liver is cirrhotic, we examine the expected path of the needle using duplex and color flow Doppler to avoid any portosystemic venous collaterals that might be in the way. We try to perform a biopsy on all masses by advancing the coaxial needle through a cuff of normal liver tissue down to the surface of the mass when possible. Taking into account the size of the lesion, we take our sample from the outer one third of the mass and avoid the center, which may have pathologically nondiagnostic necrotic tissue. If the mass is 2.0 cm or less, we take our specimen from its center. The ability to perform biopsies on small masses depends not only on their conspicuity and skill of the operator but also on the patient's ability to hold their breath. The presence of ascites is not a contraindication to biopsy, although it can make it more difficult if it is marked in amount (Fig. 2) . This is especially true when trying to sample a mass deep in a cirrhotic liver (Fig. 3 , see Video, SDC 8, http://links.lww.com/RUQ/A55, which demonstrates a core biopsy performed on a deep liver lesion in a patient with a cirrhotic liver and ascites). In some cases, paracentesis before the procedure may be helpful.
Liver biopsies are very safe to perform when the patient's blood clotting mechanism is normal. In a series of 715 patients having liver biopsies, there were only 2 major complications because of hemorrhage (Fig. 4) and no deaths. 30 The most frequent minor complication was pain. This usually occurs at the time of the biopsy or shortly thereafter. The pain is usually mild but can be severe and is presumably due to blood or bile stretching the liver capsule 35 or intraperitoneal bleeding irritating not only the peritoneum but also the intestinal tract. Not infrequently, the pain can be referred to the shoulder, often the left. This pain is usually self-limiting and goes away within 2 hours. In some cases, we prescribe acetaminophen by mouth, but only rarely do we have to resort to intramuscular or intravascular injection of pain medication.
A pathological diagnosis can be made in 99.4% of biopsies performed for diffuse hepatocellular disease. 30 The accuracy rate for diagnosing even small liver masses has increased from 79% in 1987 to 99% in 1999.
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PANCREATIC BIOPSY
Nowadays, most pancreatic mass biopsies are performed using endoscopic ultrasound, which has largely replaced the percutaneous approach as both techniques produce similar results. 36 In cases where the endoscopic approach is not technically feasible or where it fails to yield a diagnosis, the percutaneous approach can be used. This is usually done to confirm the diagnosis of an unresectable pancreatic cancer. Masses in the head, body, and proximal tail are biopsied using an anterior approach through the abdominal wall, with the patient supine (Fig. 5) . Filling the stomach with water may allow better visualization of the mass, and the biopsy can be performed through-and-through the gastric wall if necessary. 37 A loop of small bowel may also be traversed; however, we avoid going through the colon, although others have used this approach. 38 A mass in the tail may be better approached through a left intercostal space, with the patient in the right decubitus position. Care must be taken to avoid the adjacent spleen and left colon. We use a core needle and a coaxial technique. Before advancing the needle, color flow Doppler imaging should be performed to avoid any intervening vessels. 39 This is especially advised in cases where the portal vein or splenic vein is occluded as there may be many small venous collaterals around the pancreas.
Percutaneous pancreatic biopsies are probably more risky than liver or kidney biopsies as the pancreas has many normal surrounding blood vessels, which need to be avoided. That is why biopsy of a liver metastasis, if one is present, is favored over biopsy of the primary pancreatic mass. 40 Biopsies of liver metastases also allow staging of the pancreatic disease. The other problem with making a percutaneous diagnosis is the presence of acute pancreatitis in association with the cancer. This may lead to sampling the area of inflammation rather than the tumoral tissue. Chronic pancreatitis can also be a problem as its symptoms can mimic that of pancreatic cancer. In a study of 81 patients, 54 with pancreatic cancer and 27 with chronic pancreatitis, DelMaschio et al 41 demonstrated that FNA biopsies were able to differentiate between the 2 with an accuracy of 94%.
The accuracy rate of ultrasound-guided percutaneous biopsy reported by Paulsen et al 39 was around 92.5%, and the sensitivity was 93.3%. Other authors have produced similar results.
25,38,42Y45 Some results using CT guidance show a lesser success rate; however, this could be due to the more accessible masses that are easier to have a biopsy performed on being triaged to ultrasound. 38, 46 The size of the mass also affects obtaining a diagnosis. Brandt et al 38 had a success rate of 92% for masses larger than 3 cm, whereas the rate fell to 81% for lesions smaller than 3 cm. In the same study, they demonstrated a better success rate using a larger needle (92% for 16-to 19-gauge cutting needles vs 85% for 20-to 22-gauge needles). They had better success for masses in the body/tail (93%) compared with the head (84%). The complication rate of percutaneous pancreatic biopsies (1.1%Y2.6%) can be major or minor. 38, 39, 44 Minor complications include vasovagal reactions, pain requiring narcotics, and small bleeds. Major complications include bleeding that requires treatment and acute pancreatitis (2.6%). There does not appear to be any significant difference in the rate of complications between FNAs and core biopsies. 39 Seeding of the needle tract is a rare but possible complication of percutaneous fine-needle biopsies of primary pancreatic neoplasms or pancreatic liver metastases. 47 , 48 Kosugi et al 49 performed biopsies of 73 pancreatic neoplasms using 21-gauge needles. Each lesion required 1 or 2 samples, and the needles were rinsed in 10% alcohol when a second puncture was performed. Tumor implantation along the needle tract was found in only one case 2 months after the procedure in a patient with a moderately differentiated carcinoma. This was subsequently successfully removed with no additional recurrence. 49 
SPLENIC BIOPSY
This is usually performed to ascertain the pathology of a splenic mass, usually lymphoma or a metastatic deposit ( Table 4 ). The procedure is carried out using a left intercostal approach, with the patient in the right lateral decubitus position (Fig. 6) . If the spleen/mass is large, a subcostal approach may be possible. If lymphoma is the suspected diagnosis, we perform FNAs and core biopsies using a coaxial technique as described earlier in this article. We do not perform FNAs if lymphoma is not in the differential diagnosis. Keogan et al 50 recommend traversing as little splenic tissue as possible to get to the mass, which is the opposite of what is recommended for biopsy of liver masses.
Splenic biopsies are as safe to perform as liver biopsies, assuming the patient is not coagulopathic. 50, 51 In fact, the diagnostic accuracy and major complication rates are comparable to those reported for renal and liver biopsies when using 18-gauge or smaller needles. 52 The most common major complication when it occurs is hemorrhage (Fig. 7) , which may require embolization or even emergency splenectomy. The accuracy of splenic biopsy in making a pathological diagnosis is around 84% to 91%.
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RENAL BIOPSY
Renal biopsies are performed to determine the etiology of renal parenchymal disease and the pathology of renal masses (Table 5) . 55, 56 The procedure is performed with the patient in a prone position. A pillow is placed under the abdomen in thin patients. The biopsy is taken from the lower pole of either kidney to obtain cortical tissue that contains glomeruli. An initial scan is done to evaluate the kidneys'size and echogenicity and to determine which lower pole is most amenable to biopsy. In some obese patients, the prone position will not work as the kidney may be poorly visualized or be too deep to have a biopsy performed on. In that case, the decubitus position has to be used. In this position, the kidney moves both inferiorly and anteriorly, placing it closer to the skin surface.
If the kidney is still not adequately visualized, an intercostal approach in the prone position can be attempted. This approach is technically more difficult than the other two. Visualization of the kidney is limited, making it more likely the core needle will enter the renal sinus and damage the renal collecting system or vasculature.
We do renal biopsies using an automated, spring-loaded, 18-gauge cutting needle and a coaxial technique. 23, 27 The tip of the coaxial needle is guided down to the outer capsule of the lower pole of the kidney (see Video, SDC 9, http://links.lww.com/RUQ/A56, which demonstrates core biopsy of the lower pole of the kidney in a patient with immunoglobulin A nephropathy). The biopsy is performed in suspended respiration, and 3 to 4 specimens are obtained measuring 1.3 cm in length. These are placed on individual Telfa pads moistened with nonbacteriostatic normal saline and given directly to the pathologist for processing. The need for 3 to 4 cores is dictated by the required number of glomeruli per specimen to make an accurate diagnosis. The nephrologists at our institution prefer to have at least 15 to 20 glomeruli per core. Of the 4 cores obtained, 2 are used for histology: 1 for electron microscopy and 1 for immunofluorescence microscopy.
The appropriate approach to biopsy depends on the location of the mass within the kidney and can be determined only by scanning the patient. We use the same coaxial technique that we use for parenchymal renal disease and usually obtain 3 tissue specimens that are placed in formalin (see Video, SDC 10, http://links.lww.com/RUQ/A60, which demonstrates a core biopsy performed on a large left lower pole renal mass in a patient with lymphoma).
Renal biopsies are a safe procedure; however, complications do occur and include hematoma at the biopsy site, hemorrhage that may require embolization, and pseudoaneurysm formation (Fig. 8) . 57, 58 Maya and Allon 59 performed ultrasound-guided renal biopsies in 100 outpatients to evaluate the safety of the procedure. They used 16-gauge needles and observed their patients for 8 hours following the biopsies with 1 or 2 needles passes done in 91 patients and 3 to 4 passes in the remaining 9 patients. Only 13 developed a small postprocedure perinephric hematoma, and 4 were hospitalized overnight because of a drop of greater than 4% in their hematocrit. However, none developed major complications that would require a blood transfusion or other intervention. 59 They produce a pathological diagnosis in up to 100% of patients with parenchymal renal disease and in 82% to 100% of renal masses.
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ADRENAL BIOPSY
Small adrenal masses are frequently found during CT and magnetic resonance imaging studies of the abdomen performed for other reasons. These are usually nonfunctioning adenomas unless there is a history of malignancy. 61 Even with the history of malignancy, the likelihood of metastatic disease is only 50% unless the patient has small cell carcinoma of the lung. Despite a workup using an adrenal CT or magnetic resonance imaging protocol or when indicated a CTYpositron emission tomography scan, some of the masses remain indeterminate.
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Biopsy of an adrenal gland mass is usually performed to determine if it is a metastatic lesion in a patient with a known primary. It is also indicated where there is metastatic disease, and the primary could be adrenocortical carcinoma. If a pheochromocytoma is suspected based on the clinical symptoms or imaging findings, biochemical testing (ie, measurement of fractionated metanephrines and catecholamines in a 24-hour urine specimen) should be done before performing a biopsy because of the higher risk of bleeding and hypertensive crises.
66Y68 Most of these biopsies are performed using CT guidance as many of these lesions cannot be visualized using ultrasound. 69 Occasionally, if the mass is large enough to be visualized with ultrasound, a biopsy can be performed. 69 This is done using a coaxial technique and an intercostal or subcostal approach, with the biopsy side up and the patient in the decubitus position.
In a study of biopsies of 50 indeterminate adrenal masses performed using ultrasound or CT guidance by Paulsen et al, 69 a correct diagnosis was made in 96%. These included metastatic disease (70%), adrenocortical cancer (8%), adenoma (12%), and pheochromocytoma (6%). Some authors do not recommend biopsy of a possible pheochromocytoma because of the risk of severe hypertension. 70 If this is the suspected diagnosis, this can usually be determined by clinical and laboratory methods.
PERITONEAL AND MESENTERIC BIOPSY
This is performed on mesenteric masses (intra-abdominal carcinomatosis, carcinoid) and lymph nodes (Table 6 ). We use a coaxial needle technique and check for blood vessel location using color flow Doppler before advancing the needle. Because most of these biopsies are performed based on CT findings, we make sure to note the position of loops of bowel in relation to the mass ( Fig. 9 and see Video, SDC 11, http://links.lww.com/RUQ/A61, which demonstrates a core biopsy of an omental mass obtained through a small amount of ascites in a patient with intraperitoneal carcinomatosis). One may traverse small bowel as its contents are sterile. We do not like to go through the colon; however, other authors have done so without complications. When loops of bowel are in the way, they can be displaced by putting pressure on the abdominal wall with the transducer. 71 Once the coaxial needle tip is at the biopsy site, the throw of the cutting needle should be adjusted so that the well of the needle will end up within the mass. If it extends too far beyond the mass, it may lacerate an adjacent mesenteric vessel leading to bleeding. If lymphoma is the suspected diagnosis, we perform FNAs (Fig. 10 , see Video, SDC 12, http://links.lww.com/RUQ/A62, which demonstrates FNAs of an omental implant in a patient with a history of lymphoma) with or without a coaxial needle (see Video, SDC 13, http://links.lww.com/RUQ/A63, which demonstrates FNAs of iliac lymph nodes in a patient with a remote history of breast cancer).
In a study using both CT (82%) and ultrasound guidance (18%), Souza and his colleagues 72 had a success rate of 89% on 111 patients with peritoneal/omental masses. The majority of these masses were malignant, and in patients with a known primary, the biopsy revealed a second malignant tumor in 10%. They used FNAs (58.6%), a combination of FNAs and core needles (38.7%), and core needles only (3%). They had 3 minor complications: pain requiring medication in 1 patient, hypotension requiring fluid resuscitation in another, and 1 patient had a small hematoma at the biopsy site. Another complication can be cellulitis in the abdominal wall at the needle entry site and rarely peritonitis. 73 In a study by Ho et al, 73 they made a correct diagnosis in 23 (92%) of 25 omental masses, whereas Spencer et al 74 had a lesser rate of diagnosis of 77%.
RETROPERITONEAL/PELVIC BIOPSY
Lymphadenopathy and masses in the retroperitoneum/ pelvis are often too small to have a biopsy performed on using ultrasound unless the patient is thin enough to allow visualization (Table 7) . When they are sonographically visible through the anterior abdominal with the patient supine, this approach can be used. 75 Pressure with the transducer on the anterior abdominal wall will shorten the needle path. 71 Although bowel may be traversed, careful attention should be paid to avoid mesenteric vessels. For this reason, we prefer the decubitus or prone approach through the back if this allows visualization of the lymph node/mass (Fig. 11) . In the pelvis, the transgluteal route can be used, making sure to avoid the area of the sciatic nerve.
We use a coaxial technique, and when lymphoma is suspected, we perform both FNAs and core biopsies as previously described. Using FNAs on retroperitoneal lymph nodes (mean diameter, 2.1 cm), Fisher et al 71 had a success rate of 86%. They had 1 major complication due to injury to the inferior epigastric artery that required embolization (Fig. 12) . Yarram et al 76 evaluated the effectiveness of ultrasound (60%) and CT-guided (40%) core biopsies in diagnosing pelvic masses. The majority of the masses were malignant (70%), and ultrasound guidance had an accuracy of 95.4% compared with 84.6% for CT. In a study by Memel et al, 75 they had a success rate of 91% when the lymph nodes could be visualized for biopsy.
ABDOMINAL WALL BIOPSY
Masses of the abdominal wall include primary mesenchymal mass such as a desmoid tumor and metastatic lesions (Table 8 ). These biopsies are performed using a highfrequency transducer and a freehand coaxial technique. The throw of the needle needs to be adjusted to reflect the size of the mass. The coaxial needle is brought in from the side so that the biopsy will be along the longest axis of the mass. This technique is both safe and effective. If lymphoma is the suspected diagnosis, we perform FNAs using the technique described previously (see Video, SDC 14, http://links.lww.com/RUQ/A65, 
POSTBIOPSY OBSERVATION
Following the biopsy, we assess patients for pain, and we obtain a baseline postprocedure set of vital signs in the ultrasound department. Those who had a core biopsy of a solid organ are then transferred to the postanesthesia care unit for at least 2 hours of observation in the supine position at complete bed rest. For patients undergoing renal biopsies, different authors recommend varied observation periods ranging from postprocedure hospitalization with 24 hours of rest after percutaneous renal biopsy as 33% of complications occur after 8 hours 55 to releasing patients after only 6 or 8 hours of observation. 59, 77 At our institution, when renal biopsies are performed with the nephrologists, patients are kept in the hospital overnight for an observation period, which totals approximately 18 hours, and this is usually because of associated comorbidities. So far, our nephrologists have not reported any major postbiopsy complications. Others advocate that discharging asymptomatic patients 1 hour after liver biopsies performed with an 18-gauge needle is safe and cost-effective. 78, 79 Their pulse rate, blood pressure, and O 2 saturation are monitored. We do not remeasure the hemoglobin and hematocrit. Some patients experience pain following the biopsy, which we treat with acetaminophen 650 mg given orally. Uncommonly, we have to use oxycodone orally or injectable narcotic drugs such as morphine sulfate intramuscularly to control the pain. This may prolong their stay in the postanesthesia care unit. Patients who have core biopsies of lymph nodes or FNAs of a solid organ, mass, or lymph node are discharged immediately following the procedure, provided they are asymptomatic.
Before being discharged, patients are instructed on wound care and on resumption of their medications that may have been stopped before the procedure. They are also advised to avoid vigorous activity including heavy lifting or pushing for at least 1 week. Patients are given a 24-hour number to call one of our on-call physicians in case they experience weakness, dizziness, or any new pain after going home.
The pathology report is usually available within a week. Patients are instructed to call their doctor's office at that time to make an appointment to discuss the results. We review all of our pathology reports and tabulate the results to determine our success rate in making a pathological diagnosis. Any complications are also discussed at our regular quality assurance meetings. FIGURE 12. Contrast-enhanced CT scan of the abdomen in the same patient as in Figure 11 , who developed pancreatitis after biopsy of the large retroperitoneal mass. There is a pseudocyst anterior to the pancreas (arrow). 
CONCLUSIONS
Ultrasound is a safe, effective, and convenient method for performing image-guided biopsies, often preferred as it is relatively inexpensive and portable and does not depend on ionizing radiation. It is, however, operator dependent, and its use is limited to sonographically visible lesions. We review the approach to common targets of ultrasound-guided biopsy, with specific emphasis on procedure safety and efficiency. As postbiopsy hemorrhage is the most worrisome complication, we discuss our approach to the patient's coagulation profile, including routine screening with recent complete blood count, PT, INR/aPTT, and review of coagulation-affecting medications before the procedure. It is emphasized that this is performed on an individual basis, with consideration to the patient's underlying pathology and appropriate and timely coordination with the ordering physicians. We address details of patient preparation, needle and approach selection, sample preparation with a view toward suspected pathology, and recommendations for postbiopsy observation and discharge instructions. Finally, we stress the importance of regular review of pathology reports and tabulation of results to improve future practice.
APPENDIX
Video Clip 1
Video that demonstrates deep injection of Lidocaine to the level of the biopsy site (video; Supplementary Digital Content 1, http://links.lww.com/RUQ/A48).
Video Clip 2
Video that demonstrates the biopsy needle entering and exiting the liver (video; Supplementary Digital Content 2, http://links.lww.com/RUQ/A49).
Video Clip 3
Video that demonstrates FNAs of a small focal liver lesion seen in a patient with a suspected diagnosis of lymphoma (video; Supplementary Digital Content 3, http://links.lww.com/RUQ/A50).
Video Clip 4
Video that demonstrates a biopsy of the left lobe of the liver in a patient with sarcoidosis using a short throw technique (video; Supplementary Digital Content 4, http://links.lww.com/RUQ/A51).
Video Clip 5
Video that demonstrates the technique used for a core biopsy from the left lobe of the liver, using a deep throw technique (video; Supplementary Digital Content 5, http://links.lww.com/RUQ/A52).
Video Clip 6
Video that demonstrates FNAs of a small focal liver lesion (video; Supplementary Digital Content 6, http://links.lww.com/RUQ/A53).
Video Clip 7
Video that demonstrates subsequent core biopsy of the same liver lesion as in supplement digital content 6 (video; Supplementary Digital Content 7, http://links.lww.com/RUQ/A54).
Video Clip 8
Video that demonstrates a core biopsy performed on a deep liver lesion in a patient with a cirrhotic liver and ascites (video; Supplementary Digital Content 8, http://links.lww.com/RUQ/A55).
Video Clip 9
Video that demonstrates core biopsy of the lower pole of the kidney in a patient with IGA nephropathy (video; Supplementary Digital Content 9, http://links.lww.com/RUQ/A56).
Video Clip 10
Video that demonstrates a core biopsy performed of a large left lower pole renal mass in a patient with lymphoma (video; Supplementary Digital Content 10, http://links.lww.com/RUQ/A60).
Video Clip 11
Video that demonstrates a core biopsy of an omental mass obtained through a small amount of ascites in a patient with intraperitoneal carcinomatosis (video; Supplementary Digital Content 11, http://links.lww.com/RUQ/A61).
Video Clip 12
Video that demonstrates FNAs of an omental implant in a patient with a history of lymphoma (video; Supplementary Digital Content 12, http://links.lww.com/RUQ/A62).
Video Clip 13
Video that demonstrates FNAs of iliac lymph nodes in a patient with a remote history of breast cancer (video; Supplementary Digital Content 13, http://links.lww.com/RUQ/A63).
Video Clip 14
Video that demonstrates FNAs of an anterior abdominal wall metastatic lesion in a patient with squamous cell carcinoma of the tongue (video; Supplementary Digital Content 14, http://links.lww.com/RUQ/A65).
